62 results about "Tumor progression" patented technology

Described herein are particle-driven radiogenomics systems and methods that can be used to identify imaging features for prediction of intratumoral and interstitial nanoparticle distributions in cancers (e.g., in low grade and / or high-grade brain cancers (e.g., gliomas, e.g., primary gliomas)). In certain embodiments, the systems and methods described herein extract and combine quantitative multi-dimensional data generated from structural, functional, and / or metabolic imaging. In certain embodiments, the combined multidimensional data is linked to intratumoral and interstitial nanoparticle distributions. For example, this linked data can be used to determine quantitative functional-metabolic multimodality particle-based imaging features and to predict treatment efficacy. These techniques provide an improved quantitative ability to measure treatment response and determine tumor progressions compared to traditional size-based imaging methods.

The invention discloses application of a lactic acid modified gene ENO1 inhibitor in preparation of a medicine for treating nasopharynx cancer, and relates to the technical field of biological medicines. A head and neck squamous cell carcinoma prognosis model containing seven lactylation related genes is constructed by analyzing a TCGA database, the model can effectively distinguish patient risks, the total lifetime of a high-risk group is remarkably shortened, and a risk score is an independent prognosis factor; the functions of the key gene ENO1 are deeply studied through in-vitro experiments, and experimental results show that silencing of the ENO1 gene in nasopharynx cancer 5-8F cells causes up-regulation of cell pan-lactylation level, up-regulation of MMP2 expression and down-regulation of E-cadherin expression, and migration and invasion ability of tumor cells is significantly enhanced. The prognosis model provided by the invention has an important clinical prediction value, inhibition of ENO1 can promote tumor progression through abnormal lactylation, and a new thought is provided for taking ENO1 as a treatment target.

The invention provides a pilot small-molecule compound and application thereof, the structural formula of the pilot small-molecule compound is shown in the specification, and application of the small-molecule compound in preparation of a preparation for inhibiting FGL2 activity. The pilot small molecule compound provided by the invention can be combined with FGL2 protein to play a role in inhibiting the FGL2 protein, so that the development process of tumors is slowed down.

The present invention relates to a pharmaceutical composition for use in the treatment of both low-grade and high-grade glioblastoma in a human subject. The composition comprises a synergistic combination of the following active agents: R-Ketorolac, Bumetanide, and Niflumic acid. This specific combination is designed to exert a synergistic therapeutic effect against glioblastoma by targeting multiple molecular pathways involved in tumor progression, inflammation, and ion transport. In a further aspect of the invention, there is provided a method for selecting a subpopulation of glioblastoma subjects who are responsive to the aforementioned treatment. This method comprises identifying genetic profiles predictive of a favorable therapeutic response to the combined administration of R-Ketorolac, Bumetanide, and Niflumic acid.

The invention relates to the technical field of biological medicines, and particularly discloses siRNA for inhibiting CD44v6 expression in tumors and application of the siRNA. The siRNA molecule can specifically target mRNA of CD44v6, and efficient knock-down is achieved on the gene level and the protein level (the interference efficiency reaches 70%-90%); in-vitro experiments prove that the siRNA can significantly inhibit the proliferation ability and clone formation ability of gastric cancer cells (such as AGS and HGC-27); in-vivo and in-vitro experiments further show that the siRNA can enhance the sensitivity of gastric cancer cells to a ferroptosis inducer RSL3 and generate a synergistic anti-tumor effect. The invention further provides a pharmaceutical composition containing the siRNA and application of the pharmaceutical composition in preparation of drugs for treating malignant tumors such as gastric cancer, and a new strategy and means are provided for overcoming the problem that tumor progression is fast.

Aspects of the disclosure provide a formulation for treating advanced pancreatic cancer, comprising a combination of a cannabinoid, a terpene, and a flavonoid. To enhance bioavailability and targeted delivery, the formulation is incorporated into a nanoplatform, such as a nanoemulsion, optimizing absorption and delivery to cancer cells. The nanoparticle-based composition specifically targets advanced stages of pancreatic cancer, aiming to inhibit tumor progression and improve clinical outcomes.

Provided are a recombinant adenovirus or adenoviral vector expressing GLP1 receptor agonist that shows expected anti-tumor effects and prolonged survival time in tumor-bearing subjects and the pharmaceutical composition comprising the same.

Provided are a recombinant adenovirus or adenoviral vector expressing GLP1 receptor agonist that shows expected anti-tumor effects and prolonged survival time in tumor-bearing subjects and the pharmaceutical composition comprising the same.

The invention discloses an application of a GABAA alpha 6 receptor knockout substance and a combined drug thereof in preparation of a bladder cancer treatment product. The invention provides an application of a substance for knocking out a GABAA alpha 6 receptor gene and a macrophage inhibition drug in preparation of a tumor treatment product. The invention also provides application of a substance for knocking out the GABAA alpha 6 receptor gene and a macrophage inhibition drug in preparation of a product for inhibiting tumor progression. By knocking out the GABAA alpha6 receptor gene, the regulation effect of the GABAA alpha6 receptor gene on CD8 + T cell functions is researched, the application value of the GABAA alpha6 receptor gene in bladder cancer treatment is verified, and a new strategy is provided for clinical treatment.

The invention discloses an application of charantin IV in preparation of a tumor treatment medicine. The invention provides and verifies that the charantin IV can significantly inhibit the activity of cancer cells by inducing disulfiram death of cancer cells for the first time, can further promote gefitinib to overcome the drug resistance of cancer cells and inhibit the progress of drug-resistant tumors, and provides a new direction and theoretical basis for drug research, development and treatment of gefitinib drug-resistant non-small cell lung cancer.

The invention provides application of pentenedioic acid (GC) in enhancing the anti-tumor effect of T cells through metabolic reprogramming, and belongs to the technical field of biological medicine. It is found that in the tumor development process, GC is supplemented in an exogenous mode, tumor growth can be rapidly inhibited, and the anti-tumor effect depends on a TME regulation and control mechanism. Through GC treatment, the TME immune landscape can be significantly remodeled; gC treatment not only can enhance the effector function of the CD8 + T cells, but also can delay the depletion process of the CD8 + T cells; and the infiltration CD8 + T cells in the tumor of the GC treatment group are obviously increased. Particularly, after the CD8-resistant antibody is used for removing mouse CD8 + T cells, the anti-tumor effect of GC completely disappears, and it is confirmed that the tumor inhibition effect depends on the CD8 + T cells. Therefore, the invention proves that the lysine catabolic metabolite GC, as an immunostimulatory metabolite, can shape the immune activated TME by reactivating the functions of tumor infiltrating CD8 + T cells.

The invention discloses application of amikacin in preparation of a medicine for treating melanoma, and relates to the technical field of biological medicine. The invention provides application of at least one of amikacin, pharmaceutically acceptable salts of amikacin, stereoisomers of amikacin, solvates of amikacin and polymorphic substances of amikacin in preparation of drugs for treating melanoma. In the invention, amikacin can inhibit proliferation, migration and invasion of melanoma cells; in a mouse transplantation tumor model, amikacin can also obviously delay tumor progression, and meanwhile obvious toxic reaction does not occur. Therefore, amikacin has the potential of serving as a new candidate drug for treating melanoma, can be used for treating melanoma, and provides a new research direction for reutilization of antibiotic drugs and treatment of melanoma.

According to the invention, a novel immune checkpoint molecule SIDT1 is found. The SIDT1 is a powerful T cell inhibition factor mainly expressed on CD8 < + > T cells. A series of SIDT1 inhibitors are identified in the invention. The SIDT1 inhibitor can enhance the anti-tumor CD8T cell reaction and limit tumor progression, so that a new thought is provided for treatment and prevention of related tumor patients with PD-1 treatment resistance.

The application provides application of a compound of a general formula I or a pharmaceutically acceptable salt, a hydrate, a solvate, a prodrug, a tautomer, a stereoisomer thereof as a MALT1 inhibitor, the MALT1 tumor inhibitor can inhibit the expression of a MALT1 gene or inactivate the function of a MALT1 protein, the compound of the general formula can play the role of inhibiting the expression of the MALT1 gene or inactivating the function of the MALT1 protein by affecting the expression of a MALT1 protein death domain. The screened small molecule compound can inhibit the RNA expression of a marker in tumor cells and delay tumor progression in a tumor model mouse; in addition, when the small molecule compound is combined with an immune checkpoint inhibitor, the small molecule compound can synergize with the immune checkpoint inhibitor, and the curative effect is significantly enhanced.

This application discloses the application of PLAC8 as a target in the preparation of tumor therapeutic drugs, involving the field of biomedical technology. This application clarifies that the "sympathetic nervous system-β2-AR-PLAC8-cholesterol metabolism-M2 polarization" pathway is the core driving pathway for stress-related tumor progression and chemotherapy resistance. It reveals the molecular mechanism by which PLAC8 inhibits cholesterol synthesis through phosphorylation at the S67 site, binding to the N-terminal domain of SREBP2, recruiting OGT to mediate SREBP2O-GlcNAc glycosylation. Through strategies such as gene silencing, β2-AR antagonist intervention, and targeted delivery of siPLAC8 via mannose-modified lipid nanoparticles (LNPs), the application achieved the effects of inhibiting M2 macrophage accumulation, inhibiting tumor growth, and reversing chemotherapy resistance in various tumor models, including gallbladder cancer, intrahepatic cholangiocarcinoma, and prostate cancer. Furthermore, the LNPs delivery system showed no significant toxicity. This research provides a novel therapeutic target centered on PLAC8 and a safe and effective targeted intervention strategy for stress-related tumors, highlighting its clinical translational value.

This invention discloses a traditional Chinese medicine composition for treating tumors and its preparation method, belonging to the field of traditional Chinese medicine technology. The composition comprises *Uncaria rhynchophylla*, *Prunella vulgaris*, *Astragalus membranaceus*, *Adenophora stricta*, *Ophiopogon japonicus*, *Fritillaria thunbergii*, *Curcuma zedoaria*, *Panax notoginseng*, *Atractylodes macrocephala* (fried), *Ligustrum lucidum*, *Eclipta prostrata*, and *Glycyrrhiza uralensis* (processed). The formula focuses on clearing heat and detoxifying, resolving phlegm and dissipating nodules, strengthening the body's resistance, and promoting blood circulation and removing blood stasis. It combines tonification and purgation, addressing both the root cause and symptoms, precisely targeting the core pathogenesis of tumors: deficiency of vital energy, phlegm accumulation, blood stasis, and toxin accumulation. It can inhibit tumor cell proliferation, dissipate masses, enhance the body's immunity, reduce adverse reactions to radiotherapy and chemotherapy, improve clinical symptoms, stabilize tumors, and delay tumor progression and recurrence / metastasis, showing promising clinical application prospects.

The invention discloses a lung cancer immunotherapy adverse reaction patient report management system, which relates to the technical field of medical information and comprises a data acquisition module, a phase deviation calculation module, a characteristic parameter calculation module, a real-time data processing module, a characteristic decomposition module and an evaluation generation module. The method comprises the following steps: firstly, acquiring a drug administration time sequence and multi-dimensional symptom data of a patient, calculating a phase offset at a symptom acquisition moment by using a drug administration period, constructing a periodic phase coordinate system, and mapping a symptom feature vector to the coordinate system, calculating a first characteristic parameter representing drug resonance intensity and a second characteristic parameter representing a time sequence topological relation between symptoms, constructing a multi-dimensional signal decoupling model, decomposing a symptom data vector into a first component vector and a second component vector, and generating a grading evaluation result according to module values of the two components; according to the invention, precise decoupling and identification of immune adverse reactions and tumor progression are realized, and the problem of misjudgment caused by confusion of signal sources is effectively solved.

This invention relates to the fields of microbiology and biomedicine, and particularly to a strain of *Lactobacillus brittlemi* SYSU-32 and its application in tumor treatment. This invention cultured and isolated a strain of *Lactobacillus brittlemi* (SYSU-32). Limosilactobacillus pontis SYSU-32 was deposited on September 15, 2025, at the China General Microbiological Culture Collection Center (CGMCC), with accession number CGMCC No. 35919. This strain can increase CD8+ in the tumor microenvironment. + Infiltration of T cells and cytotoxic T cells inhibits the progression of colorectal cancer. Furthermore, the combination of *Lactobacillus bridgedii* SYSU-32 with the chemotherapy drug oxaliplatin enhances the pro-apoptotic effect of oxaliplatin, further inhibiting tumor progression and metastasis.

The application discloses an exosome overexpressing a TM9SF1 gene and a preparation method and application thereof in preparation of tumor inhibiting drugs, and belongs to the technical field of biological medicines, in particular relates to an exosome overexpressing a TM9SF1 gene, wherein the nucleotide sequence of the TM9SF1 gene has a NCBI gene accession number of NM_001014842.3. The application also discloses application of the exosome overexpressing the TM9SF1 gene in preparation of tumor inhibiting drugs. The preparation method of the exosome overexpressing the TM9SF1 gene is that a plasmid overexpressing the TM9SF1 gene is transfected into HEK293T cells, and the exosome is obtained after cell culture and exosome separation and purification. The prepared exosome overexpressing the TM9SF1 gene can target colorectal cancer cells, can effectively inhibit the growth of the colorectal cancer cells and tumor progression, has a positive effect on treatment of tumor diseases, and has a relatively wide application prospect.

The invention relates to the field of biological medicine, in particular to application of sEV protein RAB7 in prognosis and treatment of triple negative breast cancer. The invention finds that the expression of RAB7 in a patient with early-stage TNBC transfer is obviously higher than that of a patient without transfer, and the RAB7 is related to poor prognosis and advanced TNBC patients. The invention discloses a molecular mechanism of the sEV protein RAB7 in tumor progression and immune system regulation, and shows that the targeted RAB7 and anti-PD-1 combined treatment has clinical potential. The sEV protein RAB7 is a potential novel prognosis prediction and recurrence and metastasis monitoring marker for non-invasive detection of TNBC and a new target for treatment of TNBC.

The invention relates to the technical field of preparations for treating thyroid cancer patients, in particular to application of an iodine-containing composition in preparation of products for treating thyroid cancer. At present, a specific guidance scheme about the optimal iodine intake does not exist for patients with differentiated thyroid cancer (DTC), especially patients with structural persistent lesions after surgery and / or radioiodine treatment. In China, although definite evidences are lacked, a large number of patients still select lifelong low-iodine diets and try to avoid iodine-induced relapse. The application of the invention overcomes prejudice and proves that low-iodine diet can promote biochemical progress of thyroid cancer on the contrary, and iodine-suitable diet can better help patients with differentiated thyroid cancer to recover, inhibit RYR1 gene expression and weaken tumor angiogenesis and cell migration ability, thereby inhibiting tumor progress.

The invention relates to an integrated multimodal artificial intelligence platform designed to function as an autonomous hospital system providing end-to-end health prevention, screening, diagnosis, treatment optimization, and longitudinal digital-twin-based monitoring. The platform introduces a closed-loop clinical architecture that continuously analyzes heterogeneous patient data including radiology, pathology, genomics, laboratory findings, longitudinal clinical records, wearable streams, and environmental exposures. A multimodal transformer (MT-X) generates a unified patient-specific representation, enabling high-precision diagnostic and prognostic inference. A novel Autonomous Screening Interval Generator (ASIG) dynamically determines individualized screening schedules based on calibrated risk models and temporal disease-evolution forecasting. A Digital Twin Engine (DTE) simulates tumor progression, metastasis probability, toxicity trajectories, and therapy response. An Adaptive Therapy Optimization Engine (ATOE), based on reinforcement learning, identifies optimal treatment strategies tailored to patient biology and system-level constraints. The invention is industrially applicable to hospitals, centers, national screening programs, tele-networks, and Al-enabled health systems. The integrated nature of the invention, the closed-loop framework, and the combination of digital-twin simulation with intelligent screening and therapy design constitute a substantial improvement beyond conventional medical Al solutions.

The application discloses application of a GABAA alpha 6 receptor knockout substance and a combination drug thereof in preparation of a bladder cancer treatment product. The application provides application of a substance for knocking out a GABAA alpha 6 receptor gene and a macrophage inhibiting drug in preparation of a tumor treatment product. The application also provides application of the substance for knocking out the GABAA alpha 6 receptor gene and the macrophage inhibiting drug in preparation of a product for inhibiting tumor progression. The application explores the regulation of CD8+ T cell function by knocking out the GABAA alpha 6 receptor gene, verifies the application value of the GABAA alpha 6 receptor gene in bladder cancer treatment, and provides a new strategy for clinical treatment.

The invention discloses an R-configuration telomerase inhibitor and application thereof, and belongs to the technical field of medicinal chemistry. The prepared R-configuration telomerase inhibitor has telomerase inhibition activity obviously superior to that of a racemate of the R-configuration telomerase inhibitor, and the anti-tumor activity of the R-configuration telomerase inhibitor in various tumor cell lines is obviously higher than that of the racemate of the R-configuration telomerase inhibitor. Meanwhile, the R-configuration telomerase inhibitor has a definite effect of remodeling an anti-tumor immune microenvironment in vivo, can effectively inhibit tumor progression and induce tumor tissue regression when being combined with a PD-L1 inhibitor, is high in safety, and provides a theoretical basis for combined immunotherapy.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to human serum albumin nanoparticles entrapped with alpha-mangostin as well as a preparation method and application of the human serum albumin nanoparticles. The alpha-M entrapped human serum albumin nanoparticles provided by the invention comprise an alpha-M raw material medicine and human serum albumin (HSA), the preparation method comprises the following four steps: high-pressure homogenization, rotary evaporation, degerming filtration and freeze drying. The nano delivery system has good safety and stability, and is proved to have multiple effects of immunoregulation, tumor invasion and metastasis inhibition, matrix barrier weakening and the like at cellular level and animal level; the compound can be used for preparing anti-tumor drugs including pancreatic cancer, breast cancer, colon cancer and the like, can be used for effectively inhibiting tumor progression when being combined with chemotherapy drugs, and has broad-spectrum anti-cancer application value.

The invention belongs to the field of biological medicines, and particularly relates to application of an RERG gene in regulating an RAS / ERK signal channel to influence neuroendocrine differentiation of prostate cancer. The invention provides an application of the RERG gene in preparation of a product for inhibiting the growth of tumor cells of prostatic cancer, wherein the prostatic cancer comprises neuroendocrine differentiated prostatic cancer. In the invention, knock-down of the RERG gene promotes proliferation, migration, invasion and neuroendocrine differentiation of prostate cancer; overexpression of RERG inhibits proliferation, migration, invasion and neuroendocrine differentiation of prostate cancer. In-vivo experiments prove that the knock-down RERG significantly enhances the in-vivo tumor formation ability of the prostate cancer, the overexpression RERG inhibits the in-vivo tumor formation ability of the prostate cancer, the knock-down RERG significantly promotes neuroendocrine differentiation of the prostate cancer, the overexpression RERG inhibits the neuroendocrine differentiation of the prostate cancer, the knock-down RERG significantly activates the Ras / ERK signal pathway, and the overexpression RERG inhibits the Ras / ERK signal pathway. The results further prove that the RERG plays a role in inhibiting prostatic cancer tumor progression and neuroendocrine differentiation through a Ras / ERK signal channel.

The invention relates to the field of biological medicine and immunotherapy, and particularly provides a liver cancer neoantigen vaccine based on immunopeptidomics and immunotherapy application of the liver cancer neoantigen vaccine. According to the invention, an MHC-I immunoprecipitation technology is combined with high-throughput mass spectrometry, a neoantigen short peptide group with excellent immunogenicity is identified from a liver cancer sample, and a long peptide group is obtained by extension on the basis of short peptides. The oligopeptide antigen and the long peptide antigen are respectively mixed with an adjuvant Poly (I: C) to prepare a vaccine, and a mouse liver cancer model proves that the vaccine can effectively inhibit tumor progression and induce a tumor microenvironment to be converted into an immune activation state. The invention provides a new antigen source and a vaccine form for individualized liver cancer immunotherapy, and has remarkable clinical application potential and industrialization prospect.

The invention discloses a malignant tumor treatment simulation system and method considering an immune system, and relates to the field of computational biology and medical informatics. Based on the conceptual model, constructing a mathematical model of interaction between the immune system and the malignant tumor; wherein basic dynamics of cells and factors is reduced by using an ordinary differential equation, and interaction is added on the basis; simulating and verifying the mathematical model based on the biological data to obtain an accurate mathematical model; and performing malignant tumor immunotherapy simulation based on the accurate mathematical model to obtain an immunotherapy simulation effect. By adding an immune system and an escape mechanism, the physiological process of malignant tumor invasion is perfected, an analysis tool is provided for understanding the effect of the immune system in malignant tumor progression, and a theoretical basis is also laid for optimizing an immunotherapy strategy.